Although Src inhibition‐mediated vasoconstriction may play an important role in D‐PAH, Guignabert et al. demonstrated that dasatinib causes pulmonary arterial endothelial cell dysfunction and remodeling, suggesting a second‐hit was necessary to cause overt PAH in a susceptible individual.12, 28. This evidence concerns the gene SRC and pulmonary arterial hypertension.